論文

国際誌
2022年2月

Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG2a-f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.

Monoclonal antibodies in immunodiagnosis and immunotherapy
  • Ren Nanamiya
  • Junko Takei
  • Tomokazu Ohishi
  • Teizo Asano
  • Tomohiro Tanaka
  • Masato Sano
  • Takuro Nakamura
  • Miyuki Yanaka
  • Saori Handa
  • Nami Tateyama
  • Yasuhiro Harigae
  • Masaki Saito
  • Hiroyuki Suzuki
  • Manabu Kawada
  • Mika K Kaneko
  • Yukinari Kato
  • 全て表示

41
1
開始ページ
1
終了ページ
7
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1089/mab.2021.0036

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein. Although EGFR is physiologically essential in normal cells, it contributes to tumor malignancy through gene amplification and/or protein overexpression, which augment signaling cascades in tumor cells. We previously developed an anti-human EGFR (hEGFR) monoclonal antibody (mAb), EMab-134 (mouse IgG1, kappa), which detects hEGFR and dog EGFR (dEGFR) with high sensitivity and specificity. The mouse IgG2a version of EMab-134 (134-mG2a) has antitumor effects toward mouse xenografts of hEGFR-expressing oral squamous cell carcinomas. Furthermore, 134-mG2a-f, the defucosylated version of 134-mG2a, exhibits antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in dEGFR-overexpressed CHO-K1 (CHO/dEGFR) cells and antitumor activities in mouse xenografts of CHO/dEGFR cells. Herein, the reactivity of 134-mG2a-f against canine cancer cells with endogenous dEGFR was first examined by flow cytometry and immunocytochemistry. In vitro analysis demonstrated that 134-mG2a-f highly exerted ADCC and CDC for a canine osteosarcoma cell line, D-17, which expresses endogenous dEGFR. Moreover, in vivo administration of 134-mG2a-f significantly suppressed the development of D-17 compared with the results in response to control mouse IgG. These results suggest that 134-mG2a-f exerts antitumor effects against dEGFR-expressing canine cancers, and could be valuable as part of an antibody treatment regimen for them.

リンク情報
DOI
https://doi.org/10.1089/mab.2021.0036
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35225663
ID情報
  • DOI : 10.1089/mab.2021.0036
  • PubMed ID : 35225663

エクスポート
BibTeX RIS